Your browser doesn't support javascript.
loading
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh, Karama; Lluch, Ana; Goytain, Angela; Barrios, Carlos; Wang, Xue Q; Torrecillas, Laura; Gao, Dongxia; Ruiz-Borrego, Manuel; Leung, Samuel; Bines, José; Guerrero-Zotano, Ángel; García-Sáenz, Jose Ángel; Cejalvo, Juan Miguel; Herranz, Jesus; Torres, Roberto; Haba-Rodriguez, Juan de la; Ayala, Francisco; Gómez, Henry; Rojo, Federico; Nielsen, Torsten O; Martin, Miguel.
Afiliação
  • Asleh K; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
  • Lluch A; Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Goytain A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Barrios C; Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Wang XQ; Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain.
  • Torrecillas L; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
  • Gao D; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre, Brazil.
  • Ruiz-Borrego M; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
  • Leung S; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
  • Bines J; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
  • Guerrero-Zotano Á; Centro Médico Nacional 20 de Noviembre ISSSTE, CDMX, Mexico.
  • García-Sáenz JÁ; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
  • Cejalvo JM; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Herranz J; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Torres R; Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
  • Haba-Rodriguez J; LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
  • Ayala F; National Cancer Institute (INCA), Brazil.
  • Gómez H; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Rojo F; Instituto Valenciano de Oncología (IVO), Valencia, Spain.
  • Nielsen TO; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Martin M; Department of Oncology and Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
Clin Cancer Res ; 29(2): 389-400, 2023 01 17.
Article em En | MEDLINE | ID: mdl-36346687
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article